Key Takeaways
- The FDA’s ODAC committee rejected AstraZeneca’s camizestrant breast cancer therapy with a 6-3 vote
- Prostate cancer treatment Truqap received positive backing with a 7-1 advisory vote
- Shares of AZN declined 1.13% to $185.25 during premarket hours
- Wall Street analysts highlighted potential “regulatory overhang” concerns after the camizestrant setback
- The company maintains confidence in camizestrant’s clinical data despite advisory panel concerns
AstraZeneca faced contrasting outcomes from FDA advisory committees on Thursday, receiving approval for one oncology treatment while another was rejected.
Shares declined 1.13% during Friday’s premarket session, trading at $185.25. The stock has retreated approximately 6.9% over the last 30 days, contrasting sharply with the S&P 500’s 9.9% gain during the identical timeframe.
The Oncologic Drugs Advisory Committee (ODAC) of the FDA evaluated two separate cancer medications from AstraZeneca during Thursday’s session — delivering opposing recommendations for each.
In the disappointing development, advisors rejected camizestrant by a 6-3 margin, an oral medication designed for first-line treatment of HR-positive, HER2-negative advanced breast cancer patients carrying ESR1 mutations.
Committee members concluded that camizestrant failed to demonstrate “meaningful benefit” for patients whose condition hadn’t yet advanced on existing therapies.
Data from the SERENA-6 clinical trial demonstrated that camizestrant achieved a 56% reduction in disease advancement or mortality. Trial participants receiving the medication experienced a median progression-free period of 16 months, versus 9.2 months for those on standard treatment protocols.
However, panelists expressed reservations regarding the completeness of crucial secondary endpoints, such as overall survival metrics and time until second disease progression, based on interim data availability.
A subsequent pre-scheduled analysis revealed statistically significant PFS2 advantages — 25.7 months compared to 19.1 months — while overall survival data continued showing favorable trends for camizestrant.
AstraZeneca expressed disappointment regarding the advisory vote while reaffirming confidence in the clinical evidence and therapeutic potential for patients.
Wall Street Analysts Express Caution
Analysts from Morgan Stanley, under the leadership of Sarita Kapila, characterized the outcome as creating “regulatory overhang and a dent to investor sentiment.”
They acknowledged that FDA approval remains within the realm of possibility, though the 6-3 advisory vote diminishes probability for the SERENA-6 indication. While the FDA maintains independence from advisory recommendations, it historically aligns with panel decisions. The agency’s final determination is anticipated in the coming period.
Advisory Committee Supports Truqap Application
The day brought positive developments as well. ODAC members voted 7-1 to recommend Truqap (capivasertib) for prostate cancer patients, specifically when combined with abiraterone and androgen deprivation therapy for those with PTEN-deficient metastatic hormone-sensitive prostate cancer.
The favorable recommendation stems from Phase 3 CAPItello-281 study findings, demonstrating a 19% decrease in disease progression or death risk.
Median radiographic progression-free survival extended to 33.2 months for patients receiving Truqap combination therapy, compared with 25.7 months for the control group.
Additional secondary measures also supported the combination approach, including postponed progression to castration-resistant disease and enhanced PSA biomarker results.
The safety data aligned with established knowledge about these treatment options, although Grade 3 or higher side effects occurred more frequently among Truqap recipients. Overall survival information continues developing but shows encouraging directional trends for the combination regimen.
AZN shares remain essentially unchanged year-to-date, while the broader S&P 500 index has advanced 4.8% during the same timeframe.
